European Association of Nuclear Medicine
Europe's nuclear medicine society, whose congress and guidelines shaped the clinical adoption of PSMA PET and lutetium radioligand therapy that began in European centres.
Overview
Founded in 1985 and based in Vienna, EANM represents nuclear medicine across Europe and publishes the European Journal of Nuclear Medicine and Molecular Imaging. Its annual congress is the largest nuclear medicine meeting in Europe and was the early forum for PSMA-PET and Lu-177 PSMA work from Heidelberg, Munich, Bad Berka and other centres before the VISION trial. EANM issues procedure guidelines with SNMMI on PSMA PET, PRRT for neuroendocrine tumours, dosimetry and FDG PET response criteria, runs the EARL accreditation programme that harmonises PET scanners across trial sites, and operates the European School of Multimodality Imaging and Therapy. It advocates on isotope supply and reimbursement for theranostics in Europe.
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-22.
Matched to European Association of Nuclear Medicine, including child institutions. 5 works · 81 citations · 80% open access · 20% clinical trials · 0% reviews.
- Smiths Lueong3 works
- Stephan A. Hahn3 works
- E. Smeets3 works
- Konstantinos Savvatakis3 works
- Rickmer Braren3 works
- Laura Godfrey3 works
- Corinna Münch3 works
- Jörg D. Hoheisel3 works
- Wilko Weichert3 works
- Irina Heid3 works
| Work | Journal | Year | Citations |
|---|---|---|---|
| Emerging and Evolving Concepts in Cancer Immunotherapy Imaging 10.1148/radiol.210518 | Radiology | 2022 | 61 |
| Summary: Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema 10.2967/jnumed.123.265560 · open access | Journal of Nuclear Medicine | 2023 | 20 |
| Additional file 3 of Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma | Figshare | 2023 | 0 |
| Additional file 5 of Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma | Figshare | 2023 | 0 |
| Additional file 4 of Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma | Figshare | 2023 | 0 |
- EANM Congress
- EARL PET accreditation
- Procedure guidelines (with SNMMI)
- European Journal of Nuclear Medicine and Molecular Imaging
- ESMIT education
Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes.
Italian nuclear medicine physician serving as President of the European Association of Nuclear Medicine.
Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.
Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.
Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.
This guideline tells doctors and insurers exactly which clinical situations justify a PSMA PET scan for prostate cancer - mainly staging higher-risk disease, investigating a PSA rise after treatment, and checking that a patient's cancer will respond to PSMA radioligand therapy - and which situations do not.
This document standardises how hospitals measure the actual radiation dose reaching a patient's kidneys and tumours during lutetium-177 treatment, laying the groundwork for shifting from a one-dose-fits-all schedule to treatment doses tailored to each patient's biology.
Similar pages
not linked directly; found by shared links- IdeaA university cyclotron network with shared regulatory files for new tracers
Shares Frederik Giesel, Heidelberg University Hospital / NCT / DKFZ, Uwe Haberkorn, FAPI PET.
- InstitutionTUM Klinikum rechts der Isar / CCC München
Shares LMU Klinikum München, FAPI PET, Theranostics, Lutetium-177 dotatate.
- InstitutionUniversity Hospital Düsseldorf / CIO Düsseldorf
Shares Frederik Giesel, Heidelberg University Hospital / NCT / DKFZ, FAPI PET, Lutetium-177 vipivotide tetraxetan.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Dosimetry, Theranostics, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan.
- Key paperVISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer
Shares Ken Herrmann, Dosimetry, Theranostics, PET/CT.
- BottleneckAuthorized user shortage for radionuclide therapy
Shares Nuclear medicine technologist and physicist workforce, Society of Nuclear Medicine and Molecular Imaging, PSMA PET, Radioligand therapy (beta emitters).
- TargetFAP
Shares Frederik Giesel, Heidelberg University Hospital / NCT / DKFZ, Uwe Haberkorn, Ken Herrmann.
- Pairing177Lu-PSMA-617 then 225Ac-PSMA rescue therapy
Shares Clemens Kratochwil, Uwe Haberkorn, Lutetium-177 vipivotide tetraxetan, Targeted alpha therapy.